We examined the association between the ∊4 allele of the apolipoprotein E gene and severity of peripheral neuropathy in 234 patients with type 2 diabetes mellitus (T2DM). Based on the Neuropathy Disability Score (NDS), patients were divided into group A (NDS ≤6: mild or no neuropathy) and group B (NDS >6: severe neuropathy). In each group, patients were further divided into ∊4 carriers and non-∊4 carriers. In multivariate analysis, a more than 5-fold increased risk of severe neuropathy was associated with ∊4 carrier status (adjusted odds ratio [aOR]: 5.26, 95% confidence interval [CI]: 2.24-12.31, P = .0001). The other significant risk factors for severe neuropathy included male gender (aOR: 2.08, 95% CI: 1.05-4.14, P = .036), diabetes duration (aOR: 1.05, 95% CI: 1.00-1.09, P = .039), and hemoglobin A1c (aOR: 1.32, 95% CI: 1.05-1.66, P = .020). In conclusion, the ∊4 carrier status appears to be associated with severe peripheral neuropathy in T2DM.
ShawJEZimmetPZGriesFAZieglerD. Epidemiology of diabetic neuropathy. In: CGriesZieglerLow, eds. Textbook of Diabetic Neuropathy. New York, NY: Thieme Verlag, 2003:64–79.
2.
YoungMJBoultonAJMacleodAFWilliamsDRSonksenPH. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia. 1993;36(2):150–154.
3.
BoultonAJ. The diabetic foot: grand overview, epidemiology and pathogenesis. Diabetes Metab Res Rev. 2008;24(suppl 1):S3–S6.
4.
EdmondsME, The diabetic foot, 2003. Diabetes Metal Res Rev. 2004;20(suppl 1):S9–S12.
5.
ZieglerD. Painful diabetic neuropathy: advantage of novel drugs over old drugs?Diabetes Care. 2009;32(suppl 2):S414–S419.
6.
TesfayeSBoultonAJDyckPJ. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010;33(10):2285–2293.
7.
DyckPJDaviesJLWilsonDMServiceFJMeltonLJ 3rdO’BrienPC. Risk factors for severity of diabetic polyneuropathy: intensive longitudinal assessment of the Rochester Diabetic Neuropathy Study cohort. Diabetes Care. 1999:22(9):1479–1486.
8.
VárkonyiTKemplerP. Diabetic neuropathy: new strategies for treatment. Diabetes Obes Metab. 2008;10(2):99–108.
9.
PapanasNVinikAIZieglerD. Neuropathy in prediabetes: does the clock start ticking early. Nat Rev Endocrinol. 2011;7(11):682–690.
10.
SiveniusKPihlajamakiJPartanenJNiskanenLLaaksoMUusitupaM. Aldose reductase gene polymorphisms and peripheral nerve function in patients with type 2 diabetes. Diabetes Care. 2004;27(8):2021–2026.
11.
WayKJKataiNKingGL. Protein kinase C and the development of diabetic vascular complications. Diabet Med. 2001;18(12):945–959.
12.
VaguePDufayetDCosteTMoriscotCJannotMFRaccahD. Association of diabetic neuropathy with Na/K ATPase gene polymorphism. Diabetologia. 1997;40(5):506–511.
13.
PapanasNPapatheodorouKPapazoglouDKotsiouSChristakidisDMaltezosM. An insertion/deletion polymorphism in the Alpha2B adrenoreceptor gene is associated with peripheral neuropathy in patients with type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes. 2007;115(5):327–330.
14.
AnjaneyuluMBerent-SpillsonARusselJW. Metabotropic glutamate receptors (mGluRs) and diabetic neuropathy. Curr Drug Targets. 2008;9(1):85–93.
15.
FacerPCasulaMASmithGD. Differential expression of the capsaicin receptor TRPV I and related novel receptors TRPV3, TRPV4 and TRPM8 in normal human tissues and changes in traumatic and diabetic neuropathy. BMC Neurol. 2007;7:11.
16.
Voron’koOELakuninaNIuStrokovIALavrovaINNosikovVV.[Association of polymorphic markers of the lipid metabolism genes with diabetic neuropathy in type 1 diabetes mellitus.]Mol Biol (Mosk). 2005;39(2):230–234.
17.
MahleyRW. Apolipoprotein E cholesterol transport protein with expanding role in cell biology. Science. 1988;240(4852):622–630.
18.
OrdovasJMLitwack-KleinLWilsonPWSchaeferMMSchaeferEJ. Apolipoprotein E isoform phenotyping methodology and population frequency with identification of apoE1 and apoE5 isoforms. J Lipid Res. 1987;28(4):371–380.
19.
Hixxson JE VernierDT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with Hha I. J Lipid Res. 1990;31(3):545–548.
20.
BedlackRSStrittmatterWJMorgenlanderJC. Apolipoprotein E and neuromuscular disease: a critical review of literature. Arch Neurol. 2000;57(11):1561–1565.
21.
MiyataMSmithJD. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nat Genet. 1996;14(1):55–61.
22.
BoylesJPitasRWilsonEMahleyRWTaylorJM. Apolipoprotein E associated with astrocytic glia of the central nervous system and with nonmyelinating glia of the peripheral nervous system. J Clin Invest. 1985;76(4):1501–1513.
23.
SkeneJShooterE. Denervated sheath cells secrete a new protein after nerve injury. Proc Natl Acad Sci U S A. 1983;80(13):4169–4173.
24.
GelmanBBRifaiNGoodrumJFBouldinTWKrigmanMR. Apolipoprotein E is released by rat sciatic nerve during segmental demyelination and remyelination. J Neuropathol Exp Neurol. 1987;46(6):644–652.
25.
TsuzukiSMuranoTWatanabeHItohYMiyashitaYShiraiK.[The examination of apoE phenotypes in diabetic patients with peripheral neuropathy.]Rinsho Byori. 1998;46(8):829–833.
26.
BedlackRSEdelmanDGibbsJW 3rd. APOE genotype is a risk factor for neuropathy severity in diabetic patients. Neurology. 2003;60(6):1022–1024.
27.
ZhouZHokeACornblathDRGriffinJWPolydefkisM. APOE epsilon4 is not a succeptibility gene in idiopathic or diabetic sensory neuropathy. Neurology. 2005;64(1):139–141.
28.
PaisleyANAbbottCAvan SchieCHBoultonAJ. A comparison of the Neuropen against standard quantitative sensory-threshold measures for assessing peripheral nerve function. Diabet Med. 2002;19(5):400–405.
29.
PapanasNPapatheodorouKPapazoglouDMonastiriotisCChristakidisDMaltezosE. A comparison of the new indicator test for sudomotor function (Neuropad®) with the vibration perception threshold and the clinical examination in the diagnosis of peripheral neuropathy in subjects with type 2 diabetes. Exp Clin Endocrinol Diabetes. 2008;116(2):135–138.
30.
AbbottCACarringtonALAsheH. The North-West Diabetes Foot Care Study: incidence of, and risk factors for, new diabetic foot ulceration in a community-based patient cohort. Diabet Med. 2002;19(5):377–384.
31.
MillerSADykesDDPoleskyHF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16(3):1215.
32.
ReymerPWGroenemeyerBEvan de BurgRKasteleinJJ. Apolipoprotein E genotyping on agarose gels. Clin Chem. 1995;41(7):1046–1047.
33.
KarpouzisACaridhaRTripsianisGMichailidisCMartinisGVeletzaSV.Apolipoprotein E gene polymorphism in psoriasis. Arch Dermatol Res. 2009;301(6):405–410.
34.
SklavounouEEconomou-PetersenEKaradimaG. Apolipoprotein E polymorphism in the Greek population. Clin Genet. 1997;52(4):216–218.
35.
KolovouGDaskalovaDMikhailidisDP. Apolipoprotein E polymorphism and atherosclerosis. Angiology. 2003;54(1):59–71.
36.
KolovouGDAnagnostopoulouKKMikhailidisDP. Association of apolipoprotein E genotype with early onset of coronary heart disease in Greek men. Angiology. 2005;56(6):663–670.
37.
PitasRBoylesJLeeSFossDMahleyRW. Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins. Biochim Biophys Acta. 1987;917(1):148–161.
38.
SmithJDMiyataMPoulinSENeveuxLMCraigWY. The relationship between apolipoprotein E and serum oxidation-related variables is apolipoprotein E phenotype dependent. Int J Clin Lab Res. 1998;28(2):116–121.
39.
Jofre-MonsenyLMinihaneAMRimbachG. Impact of apoE genotype on oxidative stress, inflammation and disease risk. Mol Nutr Food Res. 2008;52(1):131–145.
40.
MiyataMSmithJD. Apolipoprotein E allele specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nat Genet. 1996;14(1):55–61.
41.
StrittmatterWJSaundersAMSchmechelD. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer’s disease. Proc Natl Acad Sci U S A. 1993;90(5):1977–1981.
42.
StrittmatterWJRosesAD. Apolipoprotein E and Alzheimer’s disease. Proc Natl Acad Sci U S A. 1995;92(11):4725–4727.
43.
CorderESaundersAStrittmatterW. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late-onset families. Science. 1993;261(5123):921–923.
44.
CorderESaundersAMRischNJ. Protective effect of apolipoprotein E type 2 allele for late-onset Alzheimer disease. Nat Genet. 1994;7(2):180–184.
45.
WilsonPWSchaeferEJLarsonMGOrdovasJM. Apolipoprotein E alleles and risk of coronary disease. A meta-analysis. Arterioscler Thromb Vasc Biol. 1996;16(10):1250–1255.
46.
PapanasNKatsikiNPapatheodorouK. Peripheral neuropathy is associated with increased serum levels of uric acid in type 2 diabetes mellitus. Angiology. 2011;62(4):291–295.
47.
PapanasNMaltezosE. Cilostazol in diabetic neuropathy: premature farewell or new beginning?Angiology. 2011;62(8):605–608.
48.
PapanasN, Maltezos E. α-Lipoic acid, diabetic neuropathy, and Nathan’s prophecy. Angiology. 2012;63(2):81–83.
